Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 17, 2017
Pharmacy Choice - News - Front Page Healthcare News - November 17, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/17/17 - "Conotoxin Polypeptide K-Cptx-Bt102, and Method for Preparation Threof and Application Thereof" in Patent Application Approval Process (USPTO...
"Conotoxin Polypeptide K-Cptx-Bt102, and Method for Preparation Threof and Application Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lin, Zhilong; Wen, Bo; Tong, Ting; Liu, Jie; Du, Chaoqin; Mo, Fen; Peng, Chao; Shi, Qiong, filed on September 30, 2014, was
11/17/17 - "Method of Identifying Risk for Thyroid Disorder" in Patent Application Approval Process (USPTO 20170307629)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Margolin, David H., filed on May 10, 2017, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Genzyme Corporation. The following quote wa
11/17/17 - "New Indication of Cardiovascular Drugs for Preparation of Cancer Inhibition Pharmaceutical Composition" in Patent Application Approval Process...
"New Indication of Cardiovascular Drugs for Preparation of Cancer Inhibition Pharmaceutical Composition" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Chen, Chiu-Hung; Chuang, Show-Mei; Hsiao, Nai-Wan; Liang, Ruei-Yue; Tan, Xiao-Tong, filed on October 23, 2015, was
11/17/17 - /C O R R E C T I O N Caligor Holdco, LLC/
In the news release, Caligor Holdco, LLC, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group, issued 16- Nov-2017 by Caligor Holdco, LLC over PR Newswire, we are advised by the company that there have been multiple changes. Caligor Rx, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group. SECAUCUS, New Jersey
11/17/17 - AACI Rejects Administration's Proposal to Cut Reimbursement to Cancer Hospitals
The Association of American Cancer Institutes issued the following news release:. The Association of American Cancer Institutes opposes the Centers for Medicare and Medicaid Services' Medicare Programs: Hospital Outpatient Prospective Payment Systems rule, released on November 1. The rule will cut hospital 340 B reimbursement from average sales pri
11/17/17 - Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
NEW HAVEN- Achillion Pharmaceuticals, Inc. today reported preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14- day study of ACH-4471 for patients with C3 glomerulopathy or immune complex-mediated membranoproliferative glomerulonephritis. Tom Barbour, Royal Melbourne Hospital, Melbourne, Australia, Department of.
11/17/17 - Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for the Collection of Qualitative Data on Tobacco Products and Communications
Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Gen
11/17/17 - Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were presented today in a
11/17/17 - Allergan Receives Approval for Ozurdex Dexamethasone Intravitreal Implant 0.7 mg in China for the Treatment of Retinal Vein Occlusion RVO
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc announced that it has received an Imported Drugs License from the Chinese Food and Drug Administration to market Ozurdex for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion.
11/17/17 - Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis [Tehran Times (Iran)]
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin, for the treatment of hereditary ATTR amyloidosis. The rolling submission all
11/17/17 - Ambulatory Surgery Center market forecast to 2022 published by leading research firm
New report of Ambulatory Surgery Center Market Report communicates about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (mater...
11/17/17 - Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market [Ghana News Agency]
-Arcturus Therapeutics Ltd., a leading RNA medicines company, announced today the completion of its previously announced merger with Alcobra Ltd., effective as of November 15, 2017. Pursuant to the merger, the holders of shares of Arcturus Therapeutics common stock outstanding immediately prior to the merger received 0.293 shares of Alcobra ordinar
11/17/17 - AstraZeneca - FASLODEX receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication for FASLODEX, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
11/17/17 - AstraZeneca receives US FDA approval for Faslodex to treat advanced breast cancer in combo with abemaciclib [Arab Times (Kuwait)]
AstraZeneca has announced that the US Food and Drug Administration has approved a new indication for Faslodex, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
11/17/17 - Bankrupt North Philadelphia Health System could continue running Girard Medical Center [Philly.com]
Nov. 16 Philadelphia has ended negotiations with NHS Human Services on a contract under which NHS would have run drug-treatment and behavioral-health operations at Girard Medical Center and the associated Goldman Clinic, a methadone center. Both are part of the bankrupt North Philadelphia Health System. Gladstein said the city still intends to si
11/17/17 - Biotechnology and Oncology Markets Have Positive Projections
According to a report by Grand View Research, the global biotechnology market is expected to reach USD 727.1 billion by 2025. Regen Biopharma, Inc., Idera Pharmaceuticals, Inc., Inovio Pharmaceuticals Inc., OncoMed Pharmaceuticals Inc., ImmunoGen, Inc.. Development and introduction of product offerings by a number of large entities is a significant
11/17/17 - Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
PETACH TIKVA, Israel Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, C
11/17/17 - CBO: GOP Tax Bill Triggers $136 Billion in Cuts Next Year, Slashing $25 Billion From Medicare
Dina Titus, D- Nev., issued the following news release:. Dina Titus of Nevada's First Congressional District released the following statement after the Congressional Budget Office estimated that the GOP's tax scheme will slash $136 billion from Medicare, the Affordable Care Act, and other direct-spending programs if the disastrous proposal becomes
11/17/17 - Cerecor Acquires TRx Pharmaceuticals
Cerecor Inc. and TRx Pharmaceuticals, LLC today announced that the companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals, LLC and its franchise of commercial medications led by Poly-Vi-Flor and Tri-Vi-Flor and a merger agreement in which Cerecor will acquire Zylera Phar
11/17/17 - Charitable Foundations Offer a Critical Safety Net to Underinsured Patients
The Patient Access Network Foundation issued the following news release:. And the Nov. 11 Economy& Business article "Pricey specialty drugs force seniors to make hard choices" accurately highlighted the incredible dilemma faced by seniors on Medicare who need expensive specialty medications to treat their illnesses. This document was posted showing
11/17/17 - Cincinnati Children's Research Paves Way for Newly Approved Asthma Drug
Thanks in part to nearly two decades of research at Cincinnati Children's Hospital Medical Center, the FDA has approved benralizumab, the first drug designed to specifically deplete eosinophils as a treatment for asthma. The FDA approved benralizumab as an add-on maintenance treatment for severe asthma with eosinophil involvement.
11/17/17 - CMP Pharma, Inc Announces That CaroSpir, The First And Only FDA-Approved Spironolactone Oral Suspension, Is Now Available
By a News Reporter-Staff News Editor at Drug Week CMP Pharma announced that CaroSpir , the first and only FDA- approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available. CaroSpir was approved by the FDA on August 4, 2017 and is now available through normal retail distribution. CaroSpir is available in 1
11/17/17 - Concern on black marketing of epilepsy medicines [Pakistan Press International]
President of Epilepsy Foundation of Pakistan and noted neurophysician of the country, Dr Fowzia Siddiqui has expressed serious concerns on ongoing black marketing of epilepsy medicines and urged the government to take a strong notice of this human issue on urgent basis. She said hundreds of thousands of epilepsy patients have been suffering a lot d
11/17/17 - Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability; Correction
SUMMARY: The Food and Drug Administration is correcting a notice entitled "Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability" that appeared in the Federal Register of November 3, 2017. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hamps
11/17/17 - Digital Medicine Changemakers Are Center Stage at CNS Summit 2017: Otsuka and Proteus, Akili Interactive Labs, and Pear Therapeutics to Receive CNS Summit 2017 Innovation Awards
Amir Kalali, will be interviewing Dr. William Carson, CEO of Otsuka Pharmaceutical Co., Ltd., and Andrew Thompson, president and CEO of Proteus Digital Health Eddie Martucci, CEO, and Adam Gazzaley, Chief Scientific Advisor, Akili Interactive Labs, and Bakul Patel, Center Director for Digital Health, FDA at CNS Summit 2017.. Otsuka and Proteus Digi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415